Covance Blog - Sharing Innovation in Drug Development
    • FDA Takes Final Step On Manufacturing Standards of Infant Formula

      Posted by
      Published On Oct 07 2014, 3:40 AM

      FDA Takes Final Step On Manufacturing Standards of Infant FormulaAn estimated 1 million infants in the U.S. are fed formula from birth, and by the time they are three months old, about 2.7 million rely on formula for at least part of their nutrition.

      On June 9, 2014 the U.S. Food and Drug Administration released a final rule regarding the manufacturing standards of infant formula. The final rule-which amends the FDA's quality control procedures, notification, and record and reporting requirements for manufactures of infant formulas-is meant to ensure that formulas for infants without unusual medical or dietary problems are safe and support healthy growth. The rule also establishes current good manufacturing practices (CGMPs), and sets a date of September 8, 2014 for manufacturer compliance.

      According to the FDA, many companies currently manufacturing infant formula for the U.S. market already produce safe products and voluntarily apply many of the CGMPs and quality control procedures included in the final rule. In fact, FDA drafts of this rule have existed since 1986. However, this final rule will set in place federally enforceable requirements for the safety and quality of infant formula, which most infants in the U.S. rely on for some portion of their nutrition.

      The agency will be accepting comments from the public on issues or information not previously considered in the interim final rule that was set in February 2014. Below is a summary of some important items in the final rule that will affect Covance and our infant formula clients:

      Laboratories will be required to use fully validated methods (like AOAC), or scientifically valid methods, which would need to be documented.

      • Stability testing is required at four-month intervals for new products/formulations and end of shelf-life testing for all existing products. This could, at minimum, double the rate of stability testing for many companies.
      • Strict testing for Salmonella and Chronobacter, which will require a significant increase in laboratory testing.
      • Testing must be performed of every nutrient, in every lot, of finished infant formula product, eliminating the testing of "marker" units.
      • Stability testing must be performed on every type of formula that a company manufacturers, compared to "representative" products. A comprehensive study is required on any new formula and a routine stability program is required for all subsequent batches.
      • Manufacturers can request an exemption from testing every formula for a Protein Efficiency Ration (PER) if they have a validated alternative based on sound scientific principles. The official method referenced by FDA is the Covance method.

      Covance has more than 40 years of experience with the analysis of infant formula, including developing many of the official test methods. Covance scientists were members of the original Association of Analytical Communities (AOAC) Task Force-which was requested by the FDA and organized and led by FDA and industry scientists-for the development of infant formula methods. A Covance scientist also chairs the new AOAC Stakeholder Panel for Infant Formula and Adult Nutritionals (SPIFAN) methods, which other Covance scientists are also involved.

      For more information on these infant formula regulations, visit the U.S. Food and Drug Administration's website.

      Visit us at to learn more.

    This entry was posted in Food Solutions and tagged , by Bookmark the permalink

    About Darryl Sullivan

    Darryl Sullivan is the Director of Scientific and Regulatory Affairs for the Nutritional Chemistry and Food Safety Division at Covance Laboratories. Mr. Sullivan acts as the primary liaison with food, nutritional and dietary supplement companies as well as providing expertise on designing comprehensive testing programs to meet scientific and regulatory requirements. In this role he is often called upon as an expert witness for litigation and dispute resolution. He has managed numerous different departments at Covance including lab operations, research and development, client services, sample management, sample preparation and study direction, as well as a satellite laboratory in Michigan. Mr. Sullivan received his BS from the University of Wisconsin-Madison and has more than 30 years of experience in laboratory testing of food and dietary supplements. He is considered to be an expert in the field of validation of analytical methods, having served for three years as Chair of the AOAC INTERNATIONAL Official Methods Board. Mr. Sullivan was a member of the Task Force that redesigned the AOAC Standards Development Process. He is currently the Past President and Secretary of the AOAC INTERNATIONAL Board of Directors, and the Chair of the AOAC Stakeholder Panel on Infant Formula and Adult Nutritionals. He is also the Chair of the AOAC Stakeholder Panel on Dietary Supplements. He is a former member of the Board of Directors of the AOAC Research Institute. He is the Chair of the Analytical Laboratories Committee of the American Herbal Product Association, a member of the USP Council of Experts for Dietary Supplements, and is a member of the Joint Committee on Dietary Supplements of NSF. Mr. Sullivan has developed and validated hundreds of analytical methods in the areas of nutrient and residue testing, and is the author of more than 75 publications and 100 s of scientific presentations. In addition, he is the Past Chair of the AOAC Presidential Task Force on Dietary Supplements and co-editor of the book Methods of Analysis for Nutrition Labeling. He is also the co-editor of the book Improving Import Food Safety.